OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/11/22
OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID RevenueGlobeNewsWire • 05/10/22
OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ETGlobeNewsWire • 05/03/22
OraSure Technologies' Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome SamplesGlobeNewsWire • 04/07/22
OraSure Technologies' Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome SamplesGlobeNewsWire • 03/31/22
OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to RoleGlobeNewsWire • 03/22/22
OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales UpGlobeNewsWire • 02/23/22
OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ETGlobeNewsWire • 02/16/22
InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting AppGlobeNewsWire • 01/31/22
InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other VariantsGlobeNewsWire • 01/13/22
OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV VirusGlobeNewsWire • 11/30/21
OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M.GlobeNewsWire • 11/09/21
OraSure Q3 Sales, Without COVID Related Products, Jump 37%; Guides FY21 Sales Below ConsensusBenzinga • 11/04/21
OraSure Technologies' (OSUR) CEO Stephen Tang on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22GlobeNewsWire • 11/03/21
U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant DetectionGlobeNewsWire • 11/02/21